Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New accelerator for sports, health AI startups to launch at the Ion

The Collectiv Foundation and Rice University have established a sports, health and wellness startup accelerator at the Ion District’s Collectiv, a sports-focused venture capital platform.

The AI Native Dual-Use Sports, Health & Wellness Accelerator, scheduled to formally launch in March, will back early-stage startups developing AI for the sports, health and wellness markets. Accelerator participants will gain access to a host of opportunities with:

  • Mentors
  • Advisers
  • Pro sports teams and leagues
  • University athletics programs
  • Health care systems
  • Corporate partners
  • VC firms
  • Pilot projects
  • University-based entrepreneurship and business initiatives

Accelerator participants will focus on sports tech verticals inlcuding performance and health, fan experience and media platforms, data and analytics, and infrastructure.

“Houston is quickly becoming one of the most important innovation hubs at the intersection of sports, health, and AI,” Ashley DeWalt, co-founder and managing partner of The Collectiv and founder of The Collectiv Foundation, said in a news release.

“By launching this platform with Rice University in the Ion District,” he added, “we are building a category-defining acceleration engine that gives founders access to world-class research, global sports properties, hospital systems, and venture capital. This is about turning sports-validated technology into globally scalable companies at a moment when the world’s attention is converging on Houston ahead of the 2026 World Cup.”

The Collectiv accelerator will draw on expertise from organizations such as the Rice-Houston Methodist Center for Human Performance, Rice Brain Institute, Rice Gateway Project and the Texas Medical Center.

“The combination of Rice University’s research leadership, Houston’s unmatched health ecosystem, and The Collectiv’s operator-driven investment platform creates a powerful acceleration engine,” Blair Garrou, co-founder and managing partner of the Mercury Fund VC firm and a senior adviser for The Collectiv, added in the release.

Additional details on programming, partners and application timelines are expected to be announced in the coming weeks.

4 Houston-area schools excel with best online degree programs in U.S.

Top of the Class

Four Houston-area universities have earned well-deserved recognition in U.S. News & World Report's just-released rankings of the Best Online Programs for 2026.

The annual rankings offer insight into the best American universities for students seeking a flexible and affordable way to attain a higher education. In the 2026 edition, U.S. News analyzed nearly 1,850 online programs for bachelor's degrees and seven master's degree disciplines: MBA, business (non-MBA), criminal justice, education, engineering, information technology, and nursing.

Many of these local schools are also high achievers in U.S. News' separate rankings of the best grad schools.

Rice University tied with Texas A&M University in College Station for the No. 3 best online master's in information technology program in the U.S., and its online MBA program ranked No. 21 nationally.

The online master's in nursing program at The University of Texas Medical Branch in Galveston was the highest performing master's nursing degree in Texas, and it ranked No. 19 nationally.

Three different programs at The University of Houston were ranked among the top 100 nationwide:
  • No. 18 – Best online master's in education
  • No. 59 – Best online master's in business (non-MBA)
  • No. 89 – Best online bachelor's program
The University of Houston's Clear Lake campus ranked No. 65 nationally for its online master's in education program.

"Online education continues to be a vital path for professionals, parents, and service members seeking to advance their careers and broaden their knowledge with necessary flexibility," said U.S. News education managing editor LaMont Jones in a press release. "The 2026 Best Online Programs rankings are an essential tool for prospective students, providing rigorous, independent analysis to help them choose a high-quality program that aligns with their personal and professional goals."

A little farther outside Houston, two more universities – Sam Houston State University in Huntsville and Texas A&M University in College Station – stood out for their online degree programs.

Sam Houston State University

  • No. 5 – Best online master's in criminal justice
  • No. 30 – Best online master's in information technology
  • No. 36 – Best online master's in education
  • No. 77 – Best online bachelor's program
  • No. 96 – Best online master's in business (non-MBA)
Texas A&M University
  • No. 3 – Best online master's in information technology (tied with Rice)
  • No. 3 – Best online master's in business (non-MBA)
  • No. 8 – Best online master's in education
  • No. 9 – Best online master's in engineering
  • No. 11 – Best online bachelor's program
---

This article originally appeared on CultureMap.com.

Houston wearable biosensing company closes $13M pre-IPO round

fresh funding

Wellysis, a Seoul, South Korea-headquartered wearable biosensing company with its U.S. subsidiary based in Houston, has closed a $13.5 million pre-IPO funding round and plans to expand its Texas operations.

The round was led by Korea Investment Partners, Kyobo Life Insurance, Kyobo Securities, Kolon Investment and a co-general partner fund backed by SBI Investment and Samsung Securities, according to a news release.

Wellysis reports that the latest round brings its total capital raised to about $30 million. The company is working toward a Korea Securities Dealers Automated Quotations listing in Q4 2026 or Q1 2027.

Wellysis is known for its continuous ECG/EKG monitor with AI reporting. Its lightweight and waterproof S-Patch cardiac monitor is designed for extended testing periods of up to 14 days on a single battery charge.

The company says that the funding will go toward commercializing the next generation of the S-Patch, known as the S-Patch MX, which will be able to capture more than 30 biometric signals, including ECG, temperature and body composition.

Wellysis also reports that it will use the funding to expand its Houston-based operations, specifically in its commercial, clinical and customer success teams.

Additionally, the company plans to accelerate the product development of two other biometric products:

  • CardioAI, an AI-powered diagnostic software platform designed to support clinical interpretation, workflow efficiency and scalable cardiac analysis
  • BioArmour, a non-medical biometric monitoring solution for the sports, public safety and defense sectors

“This pre-IPO round validates both our technology and our readiness to scale globally,” Young Juhn, CEO of Wellysis, said in the release. “With FDA-cleared solutions, expanding U.S. operations, and a strong AI roadmap, Wellysis is positioned to redefine how cardiac data is captured, interpreted, and acted upon across healthcare systems worldwide.”

Wellysis was founded in 2019 as a spinoff of Samsung. Its S-Patch runs off of a Samsung Smart Health Processor. The company's U.S. subsidiary, Wellysis USA Inc., was established in Houston in 2023 and was a resident of JLABS@TMC.

View All Listings